DDInter255 DDInter500
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy and 2 light chains, with each light chain consisting of 215 amino acids and each heavy chain consisting of 448 amino acids with 4 intramolecular disulfides. Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis in postmenopausal women. It further received additional indication approval to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer and women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer in September 2011 and in men with osteoporosis at high risk for fracture in September 2012.
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Busulfan {u} (Compound) upregulates {v} (Gene) ABL1
ABL1 {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Busulfan {u} (Compound) downregulates {v} (Gene) DECR1
DECR1 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Busulfan {u} (Compound) upregulates {v} (Gene) ABL1
ABL1 {u} (Gene) is downregulated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Busulfan {u} (Compound) upregulates {v} (Gene) HLA-DRA
HLA-DRA {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Busulfan {u} (Compound) downregulates {v} (Gene) DECR1
DECR1 {u} (Gene) is downregulated by {v} (Compound) Imatinib
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Busulfan {u} (Compound) upregulates {v} (Gene) ABL1
ABL1 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Busulfan {u} (Compound) upregulates {v} (Gene) ABL1
ABL1 {u} (Gene) is bound by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Fingolimod
Fingolimod {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Busulfan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Busulfan (Compound) upregulates ABL1 (Gene) and ABL1 (Gene) is bound by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Busulfan (Compound) downregulates DECR1 (Gene) and DECR1 (Gene) is upregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Busulfan (Compound) upregulates ABL1 (Gene) and ABL1 (Gene) is downregulated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Busulfan (Compound) upregulates HLA-DRA (Gene) and HLA-DRA (Gene) is upregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Busulfan (Compound) downregulates DECR1 (Gene) and DECR1 (Gene) is downregulated by Imatinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Busulfan (Compound) upregulates ABL1 (Gene) and ABL1 (Gene) is bound by Nilotinib (Compound) and ABL1 (Gene) is upregulated by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Busulfan (Compound) upregulates ABL1 (Gene) and ABL1 (Gene) is bound by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fingolimod (Compound) and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Denosumab